Study findings reinforce the value of treating anemia during the transition to dialysis and illustrate the problem of ESA hyporesponsiveness.
The World Kidney Day Steering Committee has declared 2021 the year of “Living Well with Kidney Disease”.
In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo.
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
Perioperative transfusion of blood products was not associated with worse clinical outcomes or allosensitization in a study of selected kidney transplant recipients.
The Agency announced that additional clarification of clinical data was needed prior to completing the review.
In a short-term trial involving hemodialysis patients, ziltivekimab significantly improved erythropoietin resistance index.
The comparative study aimed to analyze AEs as well as estimate the associated medical costs for 4 IV iron preparations.
The new evidence further supports development of the investigational HIF-PHI, which recently also demonstrated noninferiority to darbepoetin in patients with chronic kidney disease not receiving dialysis.
Low transferrin saturation was associated with worse physical quality of life in patients with CKD, even in those free of anemia.